A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors

Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.

Maintained ECOG-PS with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: an analysis of the phase III SUNLIGHT trial.

Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study.